FDA grants orphan drug designation to ABX-1100 for the treatment of Pompe disease
Aug. 11, 2022
Aro Biotherapeutics announced that the FDA has granted orphan drug designation for ABX-1100, its investigational Centyrin-siRNA conjugate, for the treatment of Pompe disease.
